L'intérêt à découvert pour Humana donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Humana. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Humana (NYSE:HUM) Stock, Rapport sur les intérêts à découvert

Humana

Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Anthropos Capital Corporation

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

<p>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 3.4% on an annualized basis producing an average annual return of 15.43%. Currently, Humana has a market capitalization of $38.48 billion. </p>
<p><strong>Buying $1000 In HUM:</strong> If an investor had bought $1000 of HUM stock 15 years ago, it would be worth <strong>$8,712.38</strong> today based on a price of $319.57 for HUM at the time of writing.</p>
<h3>Humana's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727472623_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth $8,700 Today

<p>With the stock markets trading near highs again and the start of a lower interest rates cycle, the backdrop for mergers, spin-offs, and acquisitions continues to improve. Elevated stock prices are just as good as currency when trying to acquire another company. The Sept. 24, 2024, announcement that <strong>Smartsheet Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smar#NYSE">SMAR</a>) will be acquired by Blackstone and Vista Equity Partners for $56.50 per share or $8.4 billion is a prime example of the improving backdrop.</p>
<p>Prior to the news, plenty of speculation and rumors were swirling around about the work collaboration software provider. Investors looking for another potential and logical buyout candidate in the healthcare sector can take a close look at <strong>Surgery Partners Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>).</p>
<h2><strong>The Acute Care Boom Is Real, and Health Insurers Are Scrambling</strong></h2>
<p>The acute care boom has been a growth driver for Surgery Partners, which owns and operates surgical hospitals, centers and ambulatory facilities, providing high-quality care at lower prices than general hospitals. The acute care surge that started in the fall of 2023 shocked health insurers like <strong>Humana Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>), causing them to lower their earnings forecasts for the next two years. There was a significant rise in inpatient utilization from their Medicare Advantage members.</p>
<p>Due to the significantly lower prices, patients and insurance carriers prefer non-emergency procedures to be often handled at these specialized facilities rather than acute care hospitals. Their specialized facilities have lower overhead, more efficiency and less complexity.</p>
<p>Procedures performed at surgical centers can cost 50% less than at a traditional hospital. Many of these facilities have already negotiated rates with the major insurers, resulting in lower out-of-pocket expenses for the patients as well. Due to the lower costs, health insurance companies prefer outpatient surgical centers and ambulatory facilities over hospitals.</p>
<h2><strong>Surgery Partners Raises 2024 Revenue Forecast</strong></h2>
<p>Surgery Partners reported their second-quarter 2024 EPS of 21 cents, beating analyst expectations by a penny. Revenues rose 14.2% YoY to $762.1 million, beating consensus estimates of $735.94 million. The key metrics were strong as same-facility revenues grew 10% YoY, and same-facility cases rose 3.9% YoY. The company raised its full-year 2024 revenue forecast to at least $3.075 billion, beating consensus estimates of $3.06 billion.</p>
<h2><strong>Takeover Speculation Makes Sense for Integrated Health Care Transformation</strong></h2>
<p>Insurance carriers love Surgery Partners so much that there is speculation that <strong>UnitedHealth Group</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) may be interested in acquiring them. Private equity firms are also very interested in the nation&#39;s third-largest ambulatory surgical center (ABC) operator. As more insurers evolve into integrated healthcare companies like Kaiser Permanente and as <strong>CVS Health Co.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvs#NYSE">CVS</a>) did with its acquisition of Aetna Health Insurance, interest in Surgery Partners will continue to grow. Bain Capital is Surgery Partners&#39; largest shareholder, with a 39% stake.</p>
<h2><strong>SGRY Is Forming an Ascending Triangle Breakout </strong></h2>
<p>An ascending triangle pattern is comprised of a flat-top horizontal upper trendline resistance converging with an ascending (rising) lower trendline support to meet at the apex point. The breakout occurs when the stock surges through the upper trendline, and a breakdown occurs when the stock falls below the rising trendline.</p>
<p><img alt="Surgery Partners SGRY stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240924103837_chartq-sgry.jpg" style="height:785px; width:915px" /></p>
<p>SGRY formed the flat-top upper trendline resistance at $33.95 after it deflected two breakout attempts. This pushed shares to the rising lower trendline and indicated growing demand as buyers raised their bids. The anchored daily VWAP support is at $29.15. SGRY continues to move closer to the apex point, where it can break out through the $33.95 upper trendline or fall below the $31.75 lower trendline.</p>
<p>The daily relative strength index (RSI) is stalled at the 58-band. <strong>Fibonacci</strong><strong> </strong>(<strong>Fib) pullback support levels are at $31.08, $29.95, $28.35, and $25.78.</strong></p>
<p>Surgery Partners&#39; average consensus price target is <strong>$39.86, </strong>and its highest analyst price target is $50.00<strong>. </strong>&nbsp;</p>
<p>The article &quot;<a href="https://www.marketbeat.com/stock-ideas/heres-why-surgery-partners-could-be-the-next-hot-takeover/">Here&#39;s Why Surgery Partners Could Be the Next Hot Takeover</a>&quot; first appeared on MarketBeat.</p>


Earnings

Earnings Beats

Large Cap

Mid Cap

Health Care

Rumors

Price Target

Technicals

Markets

Analyst Ratings

General

SGRY

SMAR

Here's Why Surgery Partners Could Be the Next Hot Takeover

<p>Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Humana. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 58% leaning bullish and 35% bearish. Among these notable options, 8 are puts, totaling $417,304, and 9 are calls, amounting to $508,503.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $350.0 for Humana during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $250.0 to $350.0 over the preceding 30 days.</p>
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727196343_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$18.2</td>
<td>$17.6</td>
<td>$18.0</td>
<td>$310.00</td>
<td>$126.0K</td>
<td>543</td>
<td style="text-align: right;">78</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$11.3</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$340.00</td>
<td>$107.5K</td>
<td>290</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$53.7</td>
<td>$52.9</td>
<td>$53.65</td>
<td>$350.00</td>
<td>$85.8K</td>
<td>255</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.0</td>
<td>$28.6</td>
<td>$28.6</td>
<td>$320.00</td>
<td>$85.8K</td>
<td>366</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$290.00</td>
<td>$59.9K</td>
<td>1.2K</td>
<td style="text-align: right;">186</td>
</tr>
</tbody>
</table>
</p>
<h3>About Humana</h3>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<p>After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>With a trading volume of 402,787, the price of HUM is up by 0.03%, reaching $312.87.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $396.6666666666667.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Humana, which currently sits at a price target of $400.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $395.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $395. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Looking At Humana's Recent Unusual Options Activity

<p>Cantor Fitzgerald  analyst Sarah James   reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and maintains $395 price target.</p>


Reiteration

Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $395 Price Target

<p>Financial giants have made a conspicuous bullish move on Humana. Our analysis of options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $167,567, and 6 were calls, valued at $365,528.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $315.0 to $330.0 for Humana during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Humana options trades today is 270.0 with a total volume of 1,173.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Humana's big money trades within a strike price range of $315.0 to $330.0 over the last 30 days.</p>
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726674388_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$315.00</td>
<td>$187.5K</td>
<td style="text-align: right;">64</td>
<td style="text-align: right;">251</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$16.8</td>
<td>$12.5</td>
<td>$14.2</td>
<td>$330.00</td>
<td>$71.1K</td>
<td style="text-align: right;">701</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$14.2</td>
<td>$13.2</td>
<td>$14.2</td>
<td>$330.00</td>
<td>$71.0K</td>
<td style="text-align: right;">701</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$13.1</td>
<td>$12.0</td>
<td>$12.6</td>
<td>$315.00</td>
<td>$61.5K</td>
<td style="text-align: right;">64</td>
<td style="text-align: right;">251</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$12.3</td>
<td>$12.0</td>
<td>$12.15</td>
<td>$320.00</td>
<td>$36.4K</td>
<td style="text-align: right;">58</td>
<td style="text-align: right;">140</td>
</tr>
</tbody>
</table>
</p>
<h3>About Humana</h3>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<p>After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Humana's Current Market Status</h3>
<ul>
<li>Trading volume stands at 625,007, with HUM's price up by 1.34%, positioned at $315.99.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What The Experts Say On Humana</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $397.0.</p>
<ul>
<li>An analyst from JP Morgan persists with their Neutral rating on Humana, maintaining a target price of $396. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $395. </li>
<li>Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Humana with a target price of $400. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


<p>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 3.29% on an annualized basis producing an average annual return of 14.96%. Currently, Humana has a market capitalization of $38.73 billion. </p>
<p><strong>Buying $1000 In HUM:</strong> If an investor had bought $1000 of HUM stock 15 years ago, it would be worth <strong>$8,046.92</strong> today based on a price of $321.69 for HUM at the time of writing.</p>
<h3>Humana's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726500686_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Humana Stock In The Last 15 Years

<p>These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?</p>
<ol>
<li><strong>Rentokil Initial plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) shares plummeted 19.65% after the company revised the guidance <a href="https://www.benzinga.com//node/40814655" target="_blank" rel="noreferrer noopener">for the second half of FY24</a>.</li>
<li><strong>Ally Financial Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) stock dived 17.31% after the company&#8217;s CFO noted intensifying credit challenges among <a href="https://www.benzinga.com//node/40800069" target="_blank" rel="noreferrer noopener">borrowers at a conference</a>. Several analysts cut the <a href="https://www.benzinga.com//node/40811970" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li><strong>Moderna, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 11.26% after the company cut its R&amp;D expenses by $1.1 billion by 2027 and projected <a href="https://www.benzinga.com//node/40834547" target="_blank" rel="noreferrer noopener">2025 sales below expectations</a>. Many analysts <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered the price target</a>.</li>
<li><strong>Humana Inc.&#8217;s </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock decreased 9.93%, probably after this week&#8217;s <a href="https://www.benzinga.com/general/entertainment/24/09/40840076/trump-vs-harris-presidential-debate-viewership-tops-trump-biden-total-but-falls-short-of-re" target="_blank" rel="noreferrer noopener">Trump-Harris debate</a>.</li>
<li><strong>Tyson Foods, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) stock was down 7.57%.</li>
<li><strong>KE Holdings Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares decreased 7.14%.</li>
<li><strong>Adobe</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares lost 5.69% last week following Q3 earnings. Several analysts cut their price forecasts for<a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener"> the stock</a>.</li>
<li><strong>Ryanair Holdings plc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>) shares fell 5.38%.</li>
<li><strong>JPMorgan Chase &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) stock lost 5.05% last week after COO tempered analyst outlook.</li>
<li><strong>Devon Energy Corporation </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) fell 4.87% last week. A JP Morgan analyst maintained Devon Energy with an Overweight rating and lowered the <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $64 to $51</a>.</li>
</ol>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/09/40869287/chewy-broadcom-and-microstrategy-are-among-top-10-large-cap-stock-gainers-last-week-sep-8-sep-14-are" target="_blank" rel="noreferrer noopener">Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?</a></strong></li>
</ul>
<p><em>Photo by Lutsenko_Oleksandr on Shutterstock</em></p>


Movers

ADBE

ALLY

BEKE

MRNA

RYAAY

Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

WIIM

Shares of health insurance companies and providers are trading lower following the Trump-Harris debate.

<p>Financial giants have made a conspicuous bullish move on Humana. Our analysis of options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 40% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $256,727, and 8 were calls, valued at $527,825.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $360.0 for Humana, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Humana options trades today is 158.14 with a total volume of 1,190.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Humana's big money trades within a strike price range of $310.0 to $360.0 over the last 30 days.</p>
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725993938_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$26.7</td>
<td>$26.6</td>
<td>$26.7</td>
<td>$350.00</td>
<td>$173.5K</td>
<td style="text-align: right;">305</td>
<td style="text-align: right;">65</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.0</td>
<td>$9.9</td>
<td>$10.0</td>
<td>$315.00</td>
<td>$156.9K</td>
<td style="text-align: right;">77</td>
<td style="text-align: right;">157</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$22.2</td>
<td>$22.1</td>
<td>$22.2</td>
<td>$360.00</td>
<td>$146.5K</td>
<td style="text-align: right;">316</td>
<td style="text-align: right;">96</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.2</td>
<td>$2.75</td>
<td>$3.1</td>
<td>$330.00</td>
<td>$99.7K</td>
<td style="text-align: right;">244</td>
<td style="text-align: right;">417</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$22.3</td>
<td>$21.5</td>
<td>$22.0</td>
<td>$360.00</td>
<td>$63.8K</td>
<td style="text-align: right;">316</td>
<td style="text-align: right;">30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Humana</h3>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<p>Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>With a trading volume of 723,088, the price of HUM is up by 0.54%, reaching $345.62.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $396.5.</p>
<ul>
<li>An analyst from RBC Capital persists with their Outperform rating on Humana, maintaining a target price of $400. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $395. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $395. </li>
<li>An analyst from JP Morgan persists with their Neutral rating on Humana, maintaining a target price of $396. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Humana Unusual Options Activity For September 10

<p>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Humana, revealing an average target of $384.82, a high estimate of $407.00, and a low estimate of $349.00. This current average reflects an increase of 5.14% from the previous average price target of $366.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725566417_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Humana by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$396.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$349.00</td>
<td>$341.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$407.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$400.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$392.00</td>
<td>-</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$374.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Humana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Humana's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Humana's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Humana analyst ratings.</strong></a></p>
<h2>Delving into Humana's Background</h2>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<h3>A Deep Dive into Humana's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Humana showcased positive performance, achieving a revenue growth rate of <strong>10.44%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Humana's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>2.3%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Humana's ROE excels beyond industry benchmarks, reaching <strong>4.14%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Humana's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.36%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Humana's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.77</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Humana: 11 Analysts Share Their Views

<p>RBC Capital  analyst Ben Hendrix   maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and raises the price target from $385 to $400.</p>


RBC Capital Maintains Outperform on Humana, Raises Price Target to $400

Humana shares are trading higher after the company announced it recently published a study on senior-focused primary care.

<p><i>In collaboration with a leading researcher and professor at Harvard University, Humana's first-of-its-kind study found better access to primary care and narrowed racial and socio-economic disparities for those receiving care from senior-focused primary care organizations.</i></p>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.humana.com&amp;esheet=54116988&amp;newsitemid=20240904301644&amp;lan=en-US&amp;anchor=Humana+Inc.&amp;index=1&amp;md5=d34232cc36cf2e9f7c441209acea12f5">Humana Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), one of the nation's leading health and well-being companies, recently published a study on senior-focused primary care — a value-based care model that tailors the environment and services of clinical organizations to the unique needs of older adults. Published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.healthaffairs.org%2Fdoi%2Ffull%2F10.1377%2Fhlthaff.2023.01357&amp;esheet=54116988&amp;newsitemid=20240904301644&amp;lan=en-US&amp;anchor=Health+Affairs&amp;index=2&amp;md5=b0b463e400265a5557290e992d82eb04"><strong>Health Affairs</strong></a><strong>,</strong> this study is the first of its size and scope in analyzing this type of organization. This joint study, conducted in partnership with a leading researcher and professor at Harvard University, found better access to primary care for patients of senior-focused primary care organizations compared to other types of primary care organizations like the traditional fee-for-service model.</p>


Humana Healthcare Research And Harvard University Reveal Better Access To Primary Care For Seniors Receiving Care From Senior-Focused Primary Care Organizations In New Study

<p>Members of Humana Inc.&rsquo;s senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between September 3, 2024 and September 30, 2024. During these conferences and meetings, the Company intends to reaffirm its guidance of approximately $12.81 in diluted earnings per common share&nbsp;or approximately $16.00 in adjusted earnings per common share, in each case for the year ending December 31, 2024.</p>


Guidance

Humana  Intends To Reaffirm Its FY24 EPS Guidance At Industry Conferences And Various Other Meetings - Filing

<p><strong>Humana's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has risen 3.89% since its last report. The company recently reported that it has <strong>2.25 million shares sold short</strong>, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.47 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Humana Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725300014_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Humana has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 4.31%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into Humana's Recent Short Interest

<p><a href="https://news.sanfordhealth.org/news-release/sanford-to-end-contract-with-humana-medicare-advantage/" title="https://news.sanfordhealth.org/news-release/sanford-to-end-contract-with-humana-medicare-advantage/">https://news.sanfordhealth.org/news-release/sanford-to-end-contract-with-humana-medicare-advantage/</a></p>


Sanford Health To End Participation With Humana Medicare Advantage On Dec. 31 Due To Coverage Denials And Care Delays; Patients Encouraged To Consider Other Plans During Medicare Open Enrollment

<p><strong>Evolent Health Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) is reportedly <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">up for sale</a>. </p>
<p><strong>What Happened</strong>: The Arlington, Virginia-based software provide initiated an auction process after receiving takeover inquiries from private equity firms and healthcare providers. </p>
<p>Among the potential suitors are private equity giants <strong>TPG Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), <strong>Clayton, Dubilier &amp; Rice</strong> (CD&amp;R), and <strong>KKR &amp; Co. Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>). Notably, TPG was one of Evolent's early investors.</p>
<p>Reuters noted that health insurer <strong>Elevance Health</strong> <strong>Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has also expressed interest and may join forces with a private equity partner to pursue a deal.</p>
<p>Founded in 2011, Evolent offers software solutions to help healthcare providers and insurers transition from fee-for-service to value-based care models. The company partners with prominent industry players like <strong>Humana Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).</p>
<p><strong>Why It Matters</strong>: Evolent has seen financial challenges despite a 38% revenue increase in its latest quarter. The company struggled with lower billing rates from payer customers, leading to results below market expectations.</p>
<p>Its history of attracting acquisition interest includes a 2021 Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-09-29/walgreens-said-to-weigh-takeover-of-evolent-health" target="_blank" rel="noreferrer noopener">report</a> that <strong>Walgreens Boots Alliance, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) was considering a deal.</p>
<p>Activist investor <strong>Engaged Capital</strong> took a significant stake in Evolent in 2020 and pushed for changes to enhance shareholder value.</p>
<p><strong>Price Action: </strong>EVH stock is up 0.62% at $32.30 during the premarket session at last check Friday.</p>
<p><em>Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/08/40526625/astrazeneca-threatens-to-move-vaccine-production-amid-reduced-state-support" target="_blank" rel="noreferrer noopener">AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support</a>.</strong></li>
</ul>


streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms

<p>Financial giants have made a conspicuous bearish move on Humana. Our analysis of options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 37% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $283,585, and 2 were calls, valued at $221,900.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $335.0 and $365.0 for Humana, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Humana's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Humana's whale activity within a strike price range from $335.0 to $365.0 in the last 30 days. </p>
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724350545_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$20.0</td>
<td>$19.3</td>
<td>$19.3</td>
<td>$360.00</td>
<td>$193.0K</td>
<td style="text-align: right;">127</td>
<td style="text-align: right;">103</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$335.00</td>
<td>$77.7K</td>
<td style="text-align: right;">127</td>
<td style="text-align: right;">226</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/06/24</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$350.00</td>
<td>$72.8K</td>
<td style="text-align: right;">267</td>
<td style="text-align: right;">155</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$7.6</td>
<td>$6.8</td>
<td>$7.6</td>
<td>$352.50</td>
<td>$40.2K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/06/24</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$350.00</td>
<td>$34.0K</td>
<td style="text-align: right;">267</td>
<td style="text-align: right;">223</td>
</tr>
</tbody>
</table>
</p>
<h3>About Humana</h3>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>With a trading volume of 473,307, the price of HUM is down by -1.95%, reaching $351.59.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 69 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Humana</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $389.4.</p>
<ul>
<li>An analyst from JP Morgan has decided to maintain their Neutral rating on Humana, which currently sits at a price target of $396. </li>
<li>An analyst from TD Cowen persists with their Buy rating on Humana, maintaining a target price of $407. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $395. </li>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Humana with a target price of $400. </li>
<li>Maintaining their stance, an analyst from Deutsche Bank continues to hold a Hold rating for Humana, targeting a price of $349. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With HUM

<p>JP Morgan  analyst Lisa Gill   maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and raises the price target from $332 to $396.</p>


JP Morgan Maintains Neutral on Humana, Raises Price Target to $396

UBS updates its 'election watch' stocks to match new winning probabilities

Wall Street Breakfast: What Moved Markets

FOMC Preview: How Might Markets React After The Widely Expected Rate Cut

IHF: Healthcare Dashboard For September

UnitedHealth: We See Significant Long-Term Upside

Cigna's Express Scripts sues FTC over drug pricing report

Humana's Falling Share Price Gives Investors An Opportunity

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025

Dividend Champion, Contender, And Challenger Highlights: Week Of September 22

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA – Research Report)...

Wall Street Analysts Are Bullish on Top Healthcare Picks

AAPL

ALKS

ALLE

AMAT

AMCR

AUBN

AVGO

BANF

BBWI

BSVN

COFS

COLL

CSGS

CSWC

CTRE

CZFS

EFSC

ENSG

EPRT

ESTA

EXEL

FBNC

FCPT

FFMR

FITB

FMNB

FSFG

FSLR

GAIN

GATX

GEHC

GILD

GNTY

GSBC

GWRS

HLAN

HOFT

HRMY

IIPR

INTC

INVA

INVH

IROQ

ISTR

JKHY

KFRC

KLAC

LANC

LAND

LDOS

LECO

LOGI

MDLZ

MPWR

MSFT

NDAQ

NVDA

NXRT

OCSL

OFLX

OLED

PINE

PLOW

PNBI

POWI

QCOM

QNBC

REXR

RIVN

SMCI

STAG

STLA

STLD

TFII

TOWN

TRNO

TROW

TSCO

TSLA

VCTR

VEEV

VRSK

XRAY

YORW

Press Releases

Humana Announces New Veteran Hiring Strategy and Recognition as Top Veteran-Friendly Company

Inaugural Humana Community Day Promotes Health Benefits of Volunteerism

Humana Inc. to Present at 2024 Wells Fargo Healthcare Conference

PEOPLE Magazine Recognizes Humana as one of the Top "100 Companies That Care"

CenterWell Home Health Launches 20th Food Fundraising Drive

Humana and Evergreen Nephrology Introduce New Specialized Care Program for Patients Living with Kidney Disease

New Study from Humana Healthcare Research and Harvard University Reveals Better Access to Primary Care for Seniors Receiving Care from Senior-Focused Primary Care Organizations

Humana Earns 2024 Great Place To Work Certification

Texas A&M University Mays Business School and Humana Launch Annual Nationwide Healthcare Analytics Case Competition

Humana and Interwell Health Announce Addition of State of Florida to Value-based Kidney Care Program

Comments

Humana

Intérêt court

Humana (NYSE:HUM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL